Development of a whole cell high throughput screen for muscarinic receptor agonists

Journal of Biomolecular Screening

Volumn 2, Issue 2, 1997, Pages 79-84

  Bright, Stuart W ^a   Higginbotham, Jill D ^a   Cofield, Divann J ^b   Falcone, Julie F ^a   Bymaster, Frank P ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Sphinx Pharmaceuticals Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0345026433     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1177/108705719700200205     Document Type: Article

References (21)

1. Varghese, J., Lieberburg, I., Thorsett, E.D. (1993). Alzheimer's disease: Current therapeutic approaches. Ann. Rep. Med. Chem. 28:197.
2. Cereda, E., Brambilla, A., Ezhaya, A., Gaida, W., Mendla, K., Monferini, E., Pitsikas, N., Schiavi, G.B., Sagrada, A. (1994). Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders. Eur. J. Drag Met. Pharm. 3:179.
3. Izquierdo, I. (1987). The pathogenesis of the amnesia of Alzheimer's disease. Trends Pharm. Sci. 8:325.
4. Sims, N.R., Bowen, D.M., Smith, C.C., Flack, R.H., Davison, A. N., Snowden, J. S., Neary, D. (1980). Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet 1:333.
5. Sims, N.R., Bowen, D.M., Allen, S.J., Smith, C.C., Neary, D., Thomas, D. J., Davison, A. N. (1983). Presynaptic cholinergic dysfunction in patients with dementia. J. Neurochem. 40:503.
6. Sarter, M. (1991). Taking stock of cognition enhancers. Trends Pharm. Sci. 12:456.
7. 1 receptors. J. Pharm. Exp. Ther. 269:271.
8. Schwarz, R.D., Callahan, M.J., Davis, R.E., Jaen, J.C., Lipinski, W., Raby, C., Spencer, C.J., Tecle, H. (1994). Alzheimer's disease: Therapeutic strategies. Birkhauser, Boston, Massachusetts.
9. Traub, M., Freedman, S.B. (1992). The implication of current therapeutic approaches for the cholinergic hypothesis of dementia. Dementia 3:189.
10. Hulme, B.C., Birdsall, N.J.M., Buckley, N.J. (1990). Muscarinic receptor subtypes. Ann. Rev. Pharmacol. Toxicol. 30:633.
11. Ehlert, F.J., Roeske, W.R., Yamamura, H.I. (1994). Muscarinic receptors and novel strategies for the treatment of age-related brain disorders. Life Sci. 55:2135.
12. Schwarz, R.D., Davis, R.E., Jaen, J.C., Spencer, C.J., Tecle, H., Thomas, A.J. (1993). Characterization of muscarinic agonists in recombinant cell lines. Life Sci. 52:465.
13. 2 by inducing both calcium influx and activation of protein kinase C. J. Pharm. Exp. Ther. 255:1140.
14. Abdel-Latif, A.A. (1986). Calcium-mobilizing receptors, polyphosphoinositides, and the generation of second messengers. Pharm. Rev. 38:227.
15. Conklin, B.R., Brann, M.R., Buckley, N.J., Ma, A.L., Bonner, T.I., Axelrod, J. (1988). Stimulation of arachidonic acid release and inhibition of mitogenesis by cloned genes for muscarinic receptor subtypes stably expressed in A9 L cells. Proc. Natl. Acad. Sci. 85:8698.
16. Baumgold, J., Dyer, K., Falcone, J.F. Bymaster, F P. (1995). Comparison of second-messenger responses to muscarinic receptor stimulation in M1-transfected A9 L cells. Cell. Signal. 7:39.
17. Dorje, F., Wess, J., Lambrecht, G., Tacke, R., Mutschler, E., Brann, M.R. (1991). Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharm. Exp. Ther. 256:727.
18. Saunders, J., Freedman, S.B. (1989). The design of full agonists for the cortical muscarinic receptor. Trends Pharmacol. Sci. 10 (Suppl.):70.
19. Fisher, S.K. (1986). Inositol lipids and signal transduction at CNS muscarinic receptors. Trends Pharmacol. Sci. 7 (Suppl.):61.
20. Levine, L. (1994). α-Thrombin and trypsin use different receptors to stimulate arachidonic acid metabolism. Prostagl. 47:437.
21. Whatley, R.E., Satoh, K., Zimmerman, G.A., McIntyre, T.M., Prescott, S.M. (1994). Proliferation-dependent changes in release of arachidonic acid from endothelial cells. J. Clin. Inv. 94:1889.